Swapping Assets Now Down To Execution For GSK And Novartis
This article was originally published in The Pink Sheet Daily
Executive Summary
Being successful with products originally marketed by the other will be key to the future growth and bragging rights for two leading European Big Pharmas, GlaxoSmithKline and Novartis.
You may also be interested in...
Novartis Not Tempted To Join COVID-19 Vaccines Race
While the traditional players such as Pfizer and GSK, as well as newcomer AstraZeneca, are hot in pursuit of a COVID-19 vaccine, the Swiss major is sticking to drugs, the area where "we do have deep expertise," CEO Vas Narasimhan told journalists.
Witty Exiting GSK In 2017, Raising Questions About The Firm’s Future
GlaxoSmithKline CEO Andrew Witty will retire from the company in 2017 after nine years at the helm, opening the door to the possibility of broader change.
Witty Exiting GSK In 2017, Raising Questions About The Firm’s Future
GlaxoSmithKline CEO Andrew Witty will retire from the company in 2017 after nine years at the helm, opening the door to the possibility of broader change.